meldepliktige handler fra primærinnsidere

← Alle transaksjoner

EXACT Therapeutics AS: Primary insider notification

EXACT Therapeutics AS (EXTX) · publisert 2024-12-11 17:47 · vis på NewsWeb

Transaksjoner

PersonRolleTypeVolumPrisDatoISINHandelsplassTolket via
Investinor Direkte AS 2 a) Position/status The notification concerns a close associate of a primary insider, board member, Ann-Tove Kongsnes. nærståendeThe notification concerns a close associate of a primary insider, board member, Ann-Tove Kongsnes.other3 096 0830 NOK2024-12-11Outside of trading venue Notification of transactions by Primary Insiders and Close Associatesrules · til gjennomgang
Helene Sundt AS 2 a) Position/status The notification concerns a close associate of a primary insider, board member, Leiv Askvig. nærståendeThe notification concerns a close associate of a primary insider, board member, Leiv Askvig.other803 9550 NOK2024-12-11Outside of trading venue Notification of transactions by Primary Insiders and Close Associatesrules · til gjennomgang
PAACS Invest AS 2 a) Position/status The notification concerns a close associate of a primary insider, board member, Masha Paule Nathalie Legris Strømme. nærståendeThe notification concerns a close associate of a primary insider, board member, Masha Paule Nathalie Legris Strømme.other2 699 8420 NOK2024-12-11Outside of trading venuerules · til gjennomgang

Vedlegg

Meldingstekst

11 December 2024: Reference is made to the primary insider notification published on 3 December 2024 by EXACT Therapeutics AS ("EXACT-Tx" or the "Company") regarding the share lending agreement entered into with, among others, Investinor Direkte AS, PAACS Invest AS and Helene Sundt AS, which are close associates of primary insiders, pursuant to which they granted Carnegie AS an option to borrow ordinary shares to facilitate settlement in the Company's private placement. The new shares have today been registered in the Norwegian Register of Business Enterprises and Carnegie AS has re-delivered the shares to, among others, Investinor Direkte AS, PAACS Invest AS and Helene Sundt AS. Please see the attached notification form for further information. This information is subject to the disclosure requirements in section 5-12 of the Norwegian Securities Trading Act. For more information, please contact: Per Walday, CEO EXACT Therapeutics Email per.walday@exact-tx.com About EXACT-Tx: EXACT-Tx is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com